Home Tags HR+/HER2- patients

Tag: HR+/HER2- patients

SGN-LIV1A Demonstrates Antitumor Activity and Well-Tolerated Safety Profile in Patients with...

Data presented today from an ongoing phase I clinical trial evaluating SGN-LIV1A, an antibody-drug conjugate or ADC being developed by Seattle Genetics for the...